In 2022, MMIT launched the inaugural Patient Access Awards to recognize manufacturers who are going above and beyond to ensure that much-needed therapies get into the hands of the patients who need them.
The winners—one per therapeutic area—are determined by payer and physician stakeholders, who are surveyed as part of the MMIT quarterly Oncology Index and Biologics and Injectables Index.
In this research, payer and physician stakeholders assess and rank the performance of manufacturers across a series of factors, including the manufacturer’s overall commitment to a disease, account representative support, patient and family support programs and resources, patient copay assistance, physician education, and support and HUB services.
Learn more about MMIT’s Oncology Index and Biologics and Injectables Index.
Oncology Winners:
-
Novartis (Acute Lymphoblastic Leukemia)
-
Pfizer, Inc. (Acute Myeloid Leukemia)
-
Bristol-Myers Squibb (Chronic Myeloid Leukemia)
-
Bristol-Myers Squibb (Non-Hodgkin’s Lymphoma)
Biologics & Injectables Winners:
-
Pfizer, Inc. (Atopic Dermatitis)
-
Novo Nordisk (Diabetes)
-
Janssen Pharmaceuticals (Psoriasis)
-
Amgen (Psoriatic Arthritis)
-
Sanofi (Severe Asthma)
Previous Award Winners
Patient Access Award winners are chosen on a quarterly basis. View the previous award winners from past quarters.
Award Methodology
MMIT’s Indices team fields primary research for our Oncology Index and Biologics and Injectables Index reports with our industry-leading panel of payers and physicians to assess the current and emerging trends in a variety of therapeutic areas. In this research, the payers and physician panelists evaluate the pharmaceutical manufacturers within a given therapeutic area on their performance across a series of metrics related to patient access services. The winners of the MMIT Patient Access Award are the pharmaceutical manufacturers—one per therapeutic area—who receive the highest ratings by the panelists.
Upcoming Awards: Q3
The winners for Q3 2022 will be announced in December 2022 and will include manufacturers within the following therapeutic areas: HIV, narcolepsy, ulcerative colitis, Crohn’s disease, multiple myeloma, ovarian cancer and prostate cancer.
